Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices 42655 

locally developed intervention—New— 

National Center for HIV/AIDS, Viral 

Hepatitis, STED, and TB Prevention 

(NCHHSTP), Centers for Disease Control 

and Prevention (CDC) 

Background and Brief Description 

The National Center for HIV/AIDS, 

Viral Hepatitis, STD and TB Prevention 

is requesting approval for 20-months of 

data collection entitled, ‘‘HIV 

prevention among Latina transgender 

women: Evaluation of a locally 

developed intervention.’’ The goal of 

this study is to evaluate the efficacy of 

ChiCAS (Chicas Creando Acceso a la 

Salud [Chicas: Girls Creating Access to 

Health]), a locally developed and 

culturally congruent two-session 

Spanish-language small-group 

combination intervention designed to 

promote consistent condom use, and 

access to and participation in preexposure prophylaxis (PrEP) and 

medically supervised hormone therapy 

by HIV seronegative Hispanic/Latina 

transgender women who have sex with 

men. 

The information collected through 

this study will be used to evaluate 

whether the ChiCAS intervention is an 

effective HIV-prevention strategy by 

assessing whether exposure to the 

intervention results in improvements in 

participants’ health and HIV prevention 

behaviors. The study will compare pre- 

(baseline) and post-intervention (sixmonth) levels of HIV risk among 

participants who have received the 

intervention and participants who have 

not yet received the intervention 

(delayed-intervention group). 

This study will be carried out in five 

metropolitan areas in North Carolina: 

Ashville, NC; Charlotte, NC; Research 

Triangle (metropolitan area of 

Greensboro, Winston-Salem and High 

Point NC); Raleigh, NC; and 

Wilmington, NC. The study population 

will include 140 HIV-negative Spanishspeaking transgender women. 

Participants will be adults, at least 18 

years of age, self-identify as male-tofemale transgender or report having 

been born male and identifying as 

female, and report having sex with at 

least one man in the past six months. 

We anticipate participants will be 

comprised mainly of racial/ethnic 

minority participants under 35 years of 

age, consistent with the epidemiology of 

HIV infection among transgender 

women. 

Intervention participants will be 

recruited to the study through a 

combination of approaches, including 

traditional print advertisement, referral, 

in-person outreach, and through word of 

mouth. A quantitative assessment will 

be used to collect information for this 

study, which will be delivered at the 

time of study enrollment and again at 

six-month follow up. The assessment 

will be used to measure differences in 

sexual risk knowledge, perceptions and 

behaviors including condom use, PrEP 

use and use of medically supervised 

hormone therapy. 

Intervention mediators, including 

healthcare provider trust and 

communication skills, self-reported 

health status and healthcare access, 

community attachment and social 

support will also be measured. All 

participants will complete the 

assessment at baseline and again at sixmonth follow-up after enrolling in the 

study. The intervention group will 

participate in ChiCAS after completing 

the baseline assessment and the delayed 

intervention group will participate in 

ChiCAS after completing the six-month 

follow up assessment. 

We will also examine intervention 

experiences through in-depth interviews 

with 30 intervention group participants. 

The interviews will capture 

participants’ general experiences with 

the ChiCAS intervention, as well as 

their experiences and perceptions 

specific to the main study outcomes: 

PrEP knowledge, awareness, interest 

and use; condom skills and use; and 

hormone therapy knowledge, 

awareness, interest and use. 

It is expected that 50% of transgender 

women screened will meet study 

eligibility. We expect the initial 

screening to take approximately four 

minutes to complete. The assessment 

will take 60 minutes (one hour) to 

complete and will be administered to 

140 participants a total of two times. 

The interview will take 90 minutes (one 

and one-half hours) to complete and 

will be administered to 30 participants 

from the intervention group one time. 

There are no costs to the respondents 

other than their time. The total 

estimated annualized burden hours is 

172. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

General Public—Adults ........ Eligibility Screener ................ 140 1 3/60 7 

General Public—Adults ........ Contact Information .............. 70 1 1/60 2 

General Public—Adults ........ Assessment .......................... 70 2 1.0 140 

General Public—Adults ........ Interview ............................... 15 1 1.5 23 

Total ............................... ............................................... .............................. .............................. .............................. 172 

Jeffrey M. Zirger, 

Acting Chief, Information Collection Review 

Office, Office of Scientific Integrity, Office 

of the Associate Director for Science, Office 

of the Director, Centers for Disease Control 

and Prevention. 

[FR Doc. 2018–18180 Filed 8–22–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Management Analysis and 

Services Office, CDC, pursuant to Public 

Law 92–463. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 


daltland on DSKBBV9HB2PROD with NOTICES
42656 Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–CE19–001, Injury Control Research 

Centers. 

Dates: October 30, 2018 and 

November 2, 2018 

Time: 8:30 a.m.–5:00 p.m., EDT 

Place: The Georgian Terrace, 659 

Peachtree St. NE, Atlanta, GA, 30308 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Mikel L. Walters, M.A., Ph.D., Scientific 

Review Official, NCIPC, CDC, 4770 

Buford Highway NE, Mailstop F–63, 

Atlanta, Georgia 30341, Telephone: 

(404) 639–0913; Email: mwalters@

cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–18188 Filed 8–22–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Advisory Committee on 

Immunization Practices 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

of the Advisory Committee on 

Immunization Practices (ACIP). This 

meeting is open to the public, limited 

only by room seating. The meeting room 

accommodates 400. Time will be 

available for public comment. 

DATES: The meeting will be held on 

October 24, 2018, 8:30 a.m. to 5:15 p.m., 

EDT, and October 25, 2018, 8:30 a.m. to 

4:00 p.m. EDT. 

The public is welcome to submit 

written comments in advance of the 

meeting. Comments should be 

submitted in writing by email to the 

contact person listed in FOR FURTHER

INFORMATION CONTACT. The deadline for 

receipt is October 15, 2018. 

ADDRESSES: CDC, 1600 Clifton Road NE, 

Tom Harkin Global Communications 

Center, Kent ‘Oz’ Nelson Auditorium, 

Atlanta, GA 30329–4027. 

The meeting will be webcast live via 

the World Wide Web; for instructions 

and more information on ACIP please 

visit the ACIP website: http://

www.cdc.gov/vaccines/acip/index.html. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, CDC, NCIRD, 

telephone 404–639–8836, email ACIP@

cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the Director of the 

Centers for Disease Control and 

Prevention and appear on CDC 

immunization schedules must be 

covered by applicable health plans. 

Matters to Be Considered: The agenda 

will include discussions on child/ 

adolescent immunization schedule, 

adult immunization schedule, human 

papillomavirus vaccines, pneumococcal 

vaccines, Japanese encephalitis 

vaccines, zoster vaccine, Influenza 

vaccines, general recommendations, 

anthrax vaccine, hepatitis A vaccine, 

Pertussis vaccine, and meningococcal 

vaccines. A recommendation vote is 

scheduled for child/adolescent 

immunization schedule and adult 

immunization schedule. Agenda items 

are subject to change as priorities 

dictate. For more information on the 

meeting agenda visit https://

www.cdc.gov/vaccines/acip/meetings/ 

meetings-info.html. 

Public Comment: Written comments 

must include full name, address, 

organizational affiliation, email address 

of the speaker, topic being addressed 

and specific comments. Written 

comments must not exceed one singlespaced typed page with 1-inch margins 

containing all items above. Only those 

written comments received 10 business 

days in advance of the meeting will be 

included in the official record of the 

meeting. Public comments made in 

attendance must be no longer than 3 

minutes and the person giving 

comments must attend the public 

comment session at the start time listed 

on the agenda. Time for public 

comments may start before the time 

indicated on the agenda. The Director, 

Management Analysis and Services 

Office, has been delegated the authority 

to sign Federal Register notices 

pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–18184 Filed 8–22–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–18–18ATK; Docket No.CDC–2018– 

0075] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Understanding multi-sectoral 

collaboration for strengthening public 

health capacities in Ethiopia. The goal 

of this study is to explore multi-sectoral 

collaboration in Ethiopia, in the context 

of strengthening public health capacities 

under the Global Health Security 

Agenda. 

DATES: CDC must receive written 

comments on or before October 22, 

2018. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2018– 

0075 by any of the following methods: 


daltland on DSKBBV9HB2PROD with NOTICES